Bezlotoxumab

Kathryn Dzintars, Pharm.D., BCPS

INDICATIONS

FDA

Reduce the recurrence of Clostridium difficile infections (CDIs) in patients 18 years of age and older who are receiving antibacterial CDI drug treatment and are at high risk for CDI recurrence.

There's more to see -- the rest of this topic is available only to subscribers.

Last updated: March 4, 2018